GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Profitability Rank

Pharmala Biotech Holdings (XCNQ:MDMA) Profitability Rank : 2 (As of Feb. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Profitability Rank?

Pharmala Biotech Holdings has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Pharmala Biotech Holdings's Operating Margin % for the quarter that ended in Feb. 2024 was -247.78%. As of today, Pharmala Biotech Holdings's Piotroski F-Score is 4.


Competitive Comparison of Pharmala Biotech Holdings's Profitability Rank

For the Biotechnology subindustry, Pharmala Biotech Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Profitability Rank falls into.



Pharmala Biotech Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Pharmala Biotech Holdings has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharmala Biotech Holdings's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=-0.223 / 0.09
=-247.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Pharmala Biotech Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Pharmala Biotech Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines